-
Endo gives way and withdraws opioid painkiller after FDA pressure
pharmaphorum
July 11, 2017
Endo Pharmaceuticals has announced it will remove its Opana ER opioid painkiller from the US market, a month after the FDA requested because of the potential for abuse.
-
Endo Announces Divestiture of Grupo Farmacéutico SOMAR
americanpharmaceuticalreview
July 06, 2017
Endo International announced it has entered into a definitive agreement to sell Mexico City based Grupo Farmacéutico SOMAR to Advent International for approximately $124 million subject to customary adjustments for cash, debt and working capital.
-
Endo Reports First-Quarter 2017 Financial Results
americanpharmaceuticalreview
May 10, 2017
Endo International has reported first-quarter 2017 financial results.
-
Endo Releases Statement on FDA Advisory Committees' Vote Related to OPANA® ER
americanpharmaceuticalreview
March 17, 2017
Endo International announced that the U.S. Food and Drug Administration's (FDA) Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted 18 to eight...
-
FDA panel says benefits of Endo's Opana ER no longer outweigh risks
firstwordpharma
March 16, 2017
An FDA advisory committee voted 18 to eight with one abstention that the benefits of Endo International's reformulated Opana ER (oxymorphone) no longer outweigh its risks.
-
Endo Pharmaceuticals Issues Voluntary Nationwide Recall for One Lot of Edex (alprostadil for injecti
firstwordpharma
February 27, 2017
Endo International plc today announced that one of its operating companies, Endo Pharmaceuticals Inc. based in Malvern, Pennsylvania, is voluntarily recalling one lot of Edex® (alprostadil for injection) 10 mcg to the consumer level.
-
Endo Pharmaceuticals Issues Voluntary Nationwide Recall for One Lot of Edex®
americanpharmaceuticalreview
February 27, 2017
Endo International has announced that one of its operating companies, Endo Pharmaceuticals Inc. based in Malvern, Pennsylvania, is voluntarily recalling one lot of Edex® (alprostadil for injection) 10 mcg to the consumer level.